Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT00374868 | Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable) | completed | Phase 1 / Phase 2 | 59 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 4, 2010 | clinicaltrials |
| NCT00101608 |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
| completed |
| Phase 2 |
| 150 |
| Bristol-Myers SquibbINDUSTRY |
| 15 |
| Mar 2, 2010 |
| clinicaltrials |
| NCT00891748 | Safety Study on AdCD40L Gene Therapy for Bladder Cancer | completed | Phase 1 / Phase 2 | 12 | Uppsala UniversityOTHER | 1 | Jan 18, 2010 | clinicaltrials |
| NCT00034177 | Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium | completed | Phase 2 | 27 | Achieve Life SciencesINDUSTRY | 0 | Jun 4, 2009 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00246974 | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT | completed | Phase 2 | 125 | AstraZenecaINDUSTRY | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00696579 | Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 64 | University Of PerugiaOTHER | 1 | Jun 12, 2008 | clinicaltrials |
| NCT00393809 | Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 18 | Hebrew University of JerusalemOTHER | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00191971 | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | completed | Phase 2 | 40 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 6, 2007 | clinicaltrials |
| NCT00490880 | Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer | completed | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00491114 | Intravesical Chemotherapy Treatment of Superficial Bladder Cancer | completed | Phase 2 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 5, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00034593 | A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 3 | Jul 19, 2006 | clinicaltrials |
| NCT00035061 | A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00343356 | Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder | completed | Phase 2 | 138 | LanZhou UniversityOTHER | 0 | Jun 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jan 12, 2011source: clinicaltrials